Cardiac Adverse Effects Associated with Psychotropic Drugs

Within the drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie), severe adverse drug reactions (ADRs) in psychiatric inpatients are assessed in the naturalistic setting of routine treatment. Currently, 35 psychiatric hospitals and departments are participating. This paper focuses on severe cardiovascular ADRs due to psychotropic medications. Related to the number of patients surveyed (122,562 from 1993 to 2000), these are rare events (68 cases or 0.055 %). Imputed drug classes for probable cases were antidepressants in 0.03 % and neuroleptics in 0.019 %, but other drugs were also involved. Within the group of antidepressants, the risk for a cardiac ADR depends much on the class: SSRIs were never imputed alone, but tricyclic antidepressants were imputed alone in 0.05 %. In the group of antipsychotics, the lowest rate of cardiac ADRs was found for the group of phenothiazines (0.003 %).

Cardiovascular risk factors elevated the risk for a cardiac ADR from 0.04 % to 0.14 %. Age as an independent factor did not contribute substantially to the risk for a cardiac ADR. The data of the drug safety program in psychiatry allow some estimate of differential risk rates for cardiac ADRs with different psychotropic drug groups. The results of the project can help clinicians select the appropriate drug for patients at risk to develop cardiac ADRs.

References

• 1 Agelink M W, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T. et al . Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.  J Clin Psychopharmacol. 2001;  21 8-13
• 2 Agresti A, Coull B A. Approximate is better than ”exact” for interval estimation of binomial proportions.  Am Stat. 1998;  52 119-126
• 3 Allhoff T, Bender S, Banger M, Gastpar M, Sack S, Erbel R. et al . Atrial arrhythmia in a woman treated with fluoxetine: is there a causal relationship?.  Ann Emerg Med. 2001;  37 116-117
• 4 Buckley N A, Sanders P. Cardiovascular adverse effects of antipsychotic drugs.  Drug Safety. 2000;  23 215-228
• 5 Clopper C J, Pearson E S. The use of confidence of fiducial limits illustrated in the case of the binomial.  Biometrika. 1934;  26 404-413
• 6 Coupland N, Wilson S, Nutt D. Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems.  J Psychopharmacol. 1997;  11 83-92
• 7 Czekalla J, Kollack-Walker S, Beasley C M. Cardiac Safety Parameters of Olanzapine: Comparison With Other Atypical and Typical Antipsychotics.  J Clin Psychiatry. 2001;  62 (Suppl 2) 35-40
• 8 Fayek M, Kingsbury S J, Zada J, Simpson G M. Cardiac Effects of Antipsychotic Medications.  Psychiatr Serv. 2001;  52 607-609
• 9 Glassman A H. Cardiovascular effects of antidepressant drugs: updated.  Int Clin Psychopharmacol. 1998;  13 (Suppl 5) 25-30
• 10 Glassman A H, Bigger J T. Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death.  Am J Psychiatry. 2001;  158 1774-1782
• 11 Grohmann R, Rüther E, Schmidt LG L G (eds). Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Berlin, Heidelberg, New York; Thieme 1997
• 12 Grohmann R, Rüther E, Engel R R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI.  Pharmacopsychiatry. 1999;  32 21-28
• 13 Haffner S, Lapp H, Thürmann P A. Unerwünschte Arzneimittelwirkungen. QT-Verlängerungen und Torsade-de-Pointes-Arrhythmien.  Dtsch Med Wochenschr. 2002;  127 1022-1024
• 14 Hollister L E, Kosek J C. Sudden death during treatment with phenothiazine derivatives.  J Am Med Assoc. 1965;  192 1035-1038
• 15 Huston J R, Bell G E. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogramm.  J Am Med Assoc. 1966;  198 134-138
• 16 Kopp R, Kunitz O, Baumert J H, Rossaint R. Patientin mit Knotentachykardie nach Narkoseausleitung bei vorbestehender Medikation mit einem selektiven Serotonin-Wideraufnahmehemmer.  Anästhesiol Intensimed Notfallmed Schmerzther. 2001;  36 184-187
• 17 Leo R J, Kreeger J L, Kim K Y. Cardiomyopathy associated with clozapine.  Ann Pharmacother. 1996;  30 603-605
• 18 Newmann S C, Bland R C. Mortality in a cohort of patients with schizophrenia: a record linkage study.  Can J Psychiatry. 1991;  36 239-245
• 19 Pedrosa Gil F, Grohmann R, Rüther E. Asymptomatic Bradycardia associated with amisulpride.  Pharmacopsychiatry. 2001;  34 259-261
• 20 Reilly J G, Ayis S A, Ferrier I N, Jones S J, Thomas S HL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.  Lancet. 2000;  355 1048-1052
• 21 Reilly J G, Ayis S A, Ferrier I N, Jones S J, Thomas S HL. Thioridazine and sudden unexplained death in psychiatric in-patients.  Br J Psychiatry. 2002;  180 515-522
• 22 Rothenhäusler H B, Haberl C, Ehrentraut S, Kapfhammer H P, Weber M M. Suicide attempt by pure citalpram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker.  Pharmacopsychiatry. 2000;  33 150-152
• 23 Grohmann R, Engel R, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results.  Pharmacopsychiatry. 2004;  37 Suppl 1 S4-11